Actelion To Lose $80M After Arbitration Ruling

Law360, New York (December 22, 2009, 3:33 PM EST) -- Europe’s largest biotechnology company, Actelion Ltd., announced Tuesday that it will lose $80 million in operating profits after a California arbitration panel ordered a subsidiary to pay damages to Japan's Asahi Kasei Pharma Corp. in a dispute over a drug licensing agreement.

CoTherix Inc., an Actelion subsidiary based in California, must pay Asahi Kasei $91 million plus interest after it backed out of a licensing agreement to develop a drug to treat pulmonary arterial hypertension right after Basel, Switzerland-based Actelion acquired the company.

“Actelion is surprised...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.